HOME >> MEDICINE >> NEWS
New evidence about positive three-tier co-pay performance presented at Express Scripts 2000 Outcomes Conference

Researcher first to study and report on prescription drug benefit tool

ST. LOUIS, June 28, 2000 -- Researcher Brenda Motheral, PhD, told participants of the fourth annual Express Scripts (NASD: ESRX) Outcomes Conference, held in St. Louis, that recent data indicates three-tier co-pay prescription programs have enjoyed a great deal of success since their inception two years ago.

Motheral, the author of numerous articles in the area of outcomes research, claims database methodology and managed care, conducted the first study within the healthcare industry that documents how implementation of a three-tier prescription co-pay plan affects pharmaceutical and medical utilization and expenditures, continuation with chronic medications and the percent of enrollees affected.

She told conference participants that the relatively new co-pay structure can significantly lower payers' trend in pharmaceutical expenditures, and members are not showing evidence of medication noncompliance, as was expected by some industry experts when the three-tier medication co-pay structure was initiated three years ago.

Motheral and co-investigator, Kathi Fairman, studied two comparable preferred provider organization (PPO) groups located in the same state. The plans had nearly identical demographic profiles in terms of age, gender and incidence of chronic illness.

Group one instituted a three-tier co-pay plan in 1998, changing from a two-tier plan with a $7/$12 co-pay structure to a co-pay structure of $8/$15/$25, depending on the tier level. For the year preceding implementation, drugs that were placed on tier three (brand name/non-formulary) constituted 14 percent of prescription claims.

Group two, the control group, maintained its $7/$12 two-tier structure for the duration of the study.

The study substantiated the claim that a three-tier structure can significantly lower plan sponsors' trend in pharmaceu
'"/>

Contact: Ryan Soderstrom
rsoderst@express-scripts.com
612-837-5160
Kupper Parker Communications
27-Jun-2000


Page: 1 2 3 4 5

Related medicine news :

1. More evidence of cannabis-induced psychosis
2. Not enough evidence that multivitamins prevent infections in the elderly
3. Emotional memory study reveals evidence for a self-reinforcing loop
4. Influenza vaccination programmes for children in USA and Canada based on little evidence
5. Scientific evidence for diets: dont believe everything you read
6. New evidence of retroviral involvement in amyotrophic lateral sclerosis
7. Two studies find evidence that sunlight may have beneficial influence on cancer
8. Study finds no evidence of a cancer personality
9. Penn researchers add more evidence to demonstrate role of COX inhibitors in heart-disease risk
10. USC researchers find evidence that progesterone signaling influences ovarian cancer risk
11. Chamomile tea: New evidence supports health benefits

Post Your Comments:
(Date:4/18/2014)... turns 160 years of neuroanatomy on its head. , ... essential for the fast transmission of impulses along the ... thought, according to a new work lead by Professor ... and the University,s Department of Stem Cell and Regenerative ... Department of Molecular and Cellular Biology. , "Myelin is ...
(Date:4/18/2014)... psychologists have made a brain-related discovery that could ... , This discovery opens up the possibility that ... a specific brain activity that the researchers have ... Journal of Neuroscience has just published ... an associate professor of psychology and his doctoral ...
(Date:4/17/2014)... in benign prostate tissue was associated with high-grade, ... found even in those with low prostate-specific antigen ... Cancer Epidemiology, Biomarkers & Prevention , a ... , An analysis of prostate tissue biopsies collected ... the Prostate Cancer Prevention Trial (PCPT) found that ...
(Date:4/17/2014)... One of the most popular vaccine brands for children ... may be overlooking some cost factors when choosing vaccines, ... expensive option, according to a new study by University ... administer can be driven by numerous factors," says Sheldon ... professor of computer science and of mathematics at the ...
(Date:4/17/2014)... AURORA, Colo. (April 17, 2014) Two recent ... Medicine researcher and colleagues may help scientists develop ... virus, Yellow fever, Japanese encephalitis and other disease-causing ... of biochemistry and molecular genetics at the School ... the Howard Hughes Medical Institute, and colleagues recently ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2
(Date:1/15/2014)... is very pleased to announce the appointment of Mr. ... Mark was promoted from his current role of Chief Operating ... in Massachusetts , Mississippi ... 2012 with 20+ years of broad-based operations, sales, engineering and ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
Cached News: